PhD theses (with links to PDF files):

PhD thesis Malgosia Krajewska – June 2014

PhD thesis Nicolette Alkema – December 2015

PhD thesis Hylke Wieringa – April 2017

PhD thesis Rolf de Boer – December 2017








PhD thesis Anne Margriet Heijink – March 2018


  1. van Gijn SE, Wierenga E, van den Tempel N, Kok YP, Heijink AM, Spierings DC, Foijer, F, van Vugt MA*, Fehrmann RS*. TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells. Oncogene, in press (* corresponding author)
  2. Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Brui MAjn R, James DI, Guerrero Llobet S, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt MA, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S. Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality. Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12
  3. Hanemaaijer SH, van Gijn SE, Oosting SF, Plaat BEC, Moek KL, Schuuring EM, van der Laan BFAM, Roodenburg JLN, van Vugt MA, van der Vegt B, Fehrmann RSN. Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma. Oral Oncol. 2018 May;80:33-39.
  4. Zomerman WW, Plasschaert SLA, Conroy S, Scherpen FJ, Meeuwsen-de Boer TGJ, Lourens HJ, Guerrero Llobet S, Smit MJ, Slagter-Menkema L, Seitz A, Gidding CEM, Hulleman E, Wesseling P, Meijer L, van Kempen LC, van den Berg A, Warmerdam DO, Kruyt FAE, Foijer F, van Vugt MA, den Dunnen WFA, Hoving EW, Guryev V, de Bont ESJM, Bruggeman SWM.Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma. Cell Reports. 2018 Mar 20;22(12):3206-3216.
  5. de Jong MRW, Visser L, Huls G, Diepstra A, van Vugt MA, Ammatuna E, van Rijn RS, Vellenga E, van den Berg A, Fehrmann RSN, van Meerten T. Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach. PLoS One. 2018 Feb 28;13(2):e0193098.
  6. Schoonen PM and van Vugt MA. Never tear us a-PARP: dealing with DNA lesions during mitosis. Molecular and Cellular Oncology.  2017 Oct 31;5(1):e1382670
  7. Schoonen PM, Talens F, Stok C, Gogola E, Heijink AM, Bouwman P, Foijer F, Tarsounas M, Blatter S, Jonkers J, Rottenberg S, van Vugt MA. Progression through mitosis promotes PARP inhibitor-induced cytotoxic in homologous recombination-deficient cancer cells. Nature Communications. 2017 Jul;17:8:15981
  8. Pool, M, de Boer HR, Hooge MN, van Vugt MA, de Vries EG. Harnassing integrative omics to facilitate molecular imaging of the human growth factor Receptor family for precision medicine. Theranostics. 2017: May 27;7(7):2111-2133
  9. Talens F, Jalving M, Gietema JA, van Vugt MA. Therapeutic targeting and patient selection for cancers with homologous recombination defects. Expert Opinion in Drug Discovery. 2017 Jun;12(6):565-581
  10. Ruf S, Heberle AM, Langelaar-Makkinje M, Gelino S, Wilkinson D, Gerbeth C, Schwarz JJ, Holzwarth B, Warscheid B, Meisinger C, van Vugt MA, Baumeister R, Hansen M, Thedieck K. PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy. Autophagy. 2017 Mar 4;13(3):486-505
  11. Fedoseienko A, Wieringa HW, Wisman GB, Duiker E, Reyners AK, Hofker MH, van der Zee AG, van de Sluis B, van Vugt MANuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer. PLoS One. 2016 Oct 27;11(10):e0165385.
  12. Bense RD, Sotiriou C, Piccart-Gebhart MJ, Haanen JB, van Vugt MA, de Vries EG, Schröder CP, Fehrmann RS. Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. Journal of the National Cancer Institute. 2016 Oct 13;109(1).
  13. de Boer HR, Guerreo Llobet, van Vugt MA. Controlling the response to DNA damage by the APC/C-Cdh1. Cellular and Molecular Life Sciences. 2016 Mar;73(5):949-60.
  14. Alkema NG, Wisman, GB, van der Zee AG, van Vugt MA, de Jong S. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: different models for different questions. Drug Resistance Updates. 2016 Jan;24:55-69.
  15. Wieringa HW, van der Zee, AGJ, de Vries, EG, van Vugt MABreaking the DNA damage response in cervical cancer for treatment optimization. Cancer Treatment Reviews. 2016 Jan;42:30-40.
  16. Dickreuter E, Eke I, Krause M, Borgmann K, van Vugt MA, Cordes N. Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells. Oncogene, 2016 Mar 17;35(11):1353-62.
  17. Heijink AM, Blomen VS, Degener, F, Matsushita, FY, Bisteau, XKaldis P, Foijer F, van Vugt MA. A Haploid genetics screen identifies the G1/S transition as a determinant of Wee1 inhibitor sensitivity. Proc. Natl. Acad. Sci. U.S.A, 2015 Dec 8;112(49):15160-5
  18. Hengeveld RC, de Boer HR, Schoonen PM, de Vries EG, Lens SM, van Vugt MA. Rif1 is required for resolution of ultrafine DNA bridges in anaphase to ensure genomic instability. Developmental Cell, 2015 Aug 24;34(4):466-74.
  19. Krajewska M, Fehrmann RS, de Vries EG, van Vugt MA. Regulators of homologous recombination repair as novel targets for cancer treatment. Frontiers in Genetics,  2015 Mar 20;6:96.
  20. Peterson TR, Laplante M, van Veen E, van Vugt MA, Thorn CC, Sabatini, DM. mTORC1 regulates cytokinesis through activation of Rho-Rock signaling. 2015 arXiv.
  21. Alves IT, van Vugt MA. Plk1 Manages DNA break repair during mitosis. Cell Cycle. 2015 May 3;14(9):1356-7.
  22. Fehrmann RS, Karjalainen JM, Krajewska M, Westra HJ, Maloney D, Simeonov A, Pers TH, Hirschhorn JN, Jansen RC, Schultes EA, van Haagen HH, de Vries EG, te Meerman GJ, Wijmenga C, van Vugt MA, Franke L. Gene expression analysis identifies global gene dosage sensitivity in cancer. Nature Genetics. 2015 Feb;47(2):115-25.
  23. Tamas K, Domanska UM, van Dijk TH, Timmer-Bosscha H, Havenga K, Karrenbeld A, Sluiter WJ, Beukema JC, van Vugt MA, de Vries EG, Hospers GA, Walenkamp AM. CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment. Current Pharmaceutical Design, 2015;21(17):2276-83.
  24. Lafranchi L, de Boer HR, de Vries EG, Ong SE, Sartori AA, van Vugt MA. APC/CCdh1 controls CtIP stability during the cell cycle and in response to DNA damage. EMBO J. 2014 Dec 1;33(23):2860-79
  25. Krajewska M, Fehrmann RS, Schoonen PM, Labib S, de Vries EG, Franke L, van Vugt MA. ATR inhibition preferentially targets homologous recombination-deficient tumor cells. Oncogene. 2015 Jun;34(26):3474-81.
  26. Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA*, Wisman GB*. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer. Gynecological Oncology. 2014 Jun;133(3):591-8. (* equal contribution)
  27. Domanska UM, Boer JC, Timmer-Bosscha H, van Vugt MA, Hoving HD, Kliphuis NM, Rosati S, van der Poel HG, de Jong IJ, de Vries EG, Walenkamp AM. CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model. Clin Exp Metastasis. 2014 Oct;31(7):829-39.
  28. Koster R, van Vugt MA, Timmer-Bosscha H, Gietema JA, de Jong S. Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer. Expert Rev Mol Med. 2013 Sep 30;15:e12.
  29. Heijink AM, Krajewska M, van Vugt MA. The DNA damage response during mitosis. Mutation research, 2013 Oct;750(1-2):45-55.
  30. Huisman C, Wisman GB, Kazemier HG, van Vugt MA, van der Zee AG, Schussing E, Rots MG. Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by Artificial Transcription Factors. Molecular Oncology, 2013 Jun;7(3):669-79
  31. Krajewska M, Heijink AM, Bisselink YJ, Seinstra WI, Sillje HH, de Vries EG, van Vugt MA. Forced activation of Cdk1 via Wee1 inhibition impairs homologous recombination. Oncogene, 2013 Jun 13;32(24):3001-8
  32. Bench F, van Kruchten M, Lamberts LE, Schröder CS, Hospers GA, Brouwers AH, van Vugt MA, de Vries EG. Molecular imaging for monitoring treatment response in breast cancer patients. European Journal of Pharmacology, 2013 Oct 5;717(1-3):2-11
  33. Reyners AK, de Munck L, Erdkamp FL, Smit WM, Hoekman K, Lalisang RI, de Graaf H, Wymenga AN, Polee M, Hollema H, van Vugt MA, Schaapveld M, Willemse PH; for the DoCaCel Study Group. A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Annals of Oncology, 2012, Nov;23(11):2896-902
  34. Roossink F, Wieringa HW, Noordhuis MG, Ten Hoor KA, Kok M, Slagter-Menkema L,  Hollema H, de Bock GH, Pras E, de Vries EG, de Jong S, van der Zee AG, Schuuring E, Wisman GB, van Vugt MA. The role of ATM and 53BP1 as predictive markers in cervical cancer. International Journal of Cancer, 2012, Nov 1;131(9):2056-66
  35. de Vries EG, Oude Munnink TH, van Vugt MA, and Nagengast WB. Toward Molecular Imaging-Driven Drug Development in Oncology. Cancer Discovery, 2011, 1(1): 25-8
  36. Kooter IM, van Vugt MA, Jedynska AD, Tromp PC, Houtzager MM, Verbeek RP, Kadijk G, Mulderij M, Krul CA. Toxicological characterization of diesel engine emissions using biodiesel and a closed soot filter. Atmospheric Environment, 2011, 45,(8), 1574-1580
  37. Heijink DM, de Vries EG, Koornstra JJ, Hospers GA,Hofstra RM, van Vugt MA, de Jong S, Kleibeuker JH. Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome. Critical Reviews in Oncology and Hematology, 2011, 80(2):264-77.
  38. Krajewska M, van Vugt MA. Building a great wall around mitosis: evolutionary conserved roles for the Greatwall/MASTL kinases in securing chromosome stability. Cell Cycle,2010, 9(19):3842.
  39. Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt MA, Wang X, Linding R, Ong SE, Weaver D, Carr SA, Yaffe MB. DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Molecular Cell, 2010, 40(1):34-49.
  40. van Harn T, Foijer F, van Vugt M, Banerjee R, Yang F, Oostra A, Joenje H, te Riele H. Loss of Rb proteins causes genomic instability in the absence of mitogenic signaling. Genes and Development, 2010, 24(13):1377-88.
  41. van Vugt MA, Yaffe MB. Cell cycle re-entry mechanisms after DNA damage checkpoints: giving it some gas to shut off the breaks! Cell Cycle, 2010, 9(11):2097-101.
  42. van Vugt MA., Gardino AK, Linding R, Ostheimer G, Reinhardt HC, Tan C, Maio H, Keezer S, Li R, Pawson T, Lewis T, Brummelkamp TR, Yaffe MB. A mitotic phosphorylationfeedback network connects Cdk1, Plk1, 53BP1 and Chk2 to inactivate the G2/M DNA damage checkpoint. PLoS Biology, 2010, 8, e1000287
  43. Leuken R, Clijsters L, van Zon W, Lim D, Yao X, Wolthuis RM, Yaffe MB, Medema RH Van Vugt MA. Polo-like kinase-1 controls activation of the APC/C-Cdh1 through hCdc14A. PLoS One, 2009, 4:e5282
  44. Kishi K, van Vugt MA, Okamoto K, Hayashi Y, Yaffe MB. Functional dynamics of Polo-like kinase 1 at the centrosome. Molecular and Cellular Biology, 2009, 29:3134-50.
  45. Linding R*, Jensen LL,* Ostheimer G*, van Vugt MA, Jørgensen C, Miron IM, Diella F, Colwill K, Taylor L, Elder K, Metalnikov P, Nguyen V, Pasculescu A, Jin J, Park JG, Samson L, Woodgett JR, Russell RB, Bork P, Yaffe MB*, Pawson T*. Systematic discovery of in vivo phosphorylation networks. Cell, 2007, 129(7):1415-26 (* equal contribution)
  46. Wilker E, van Vugt MA, Artim SA, Huang PH, Petersen CP, Reinhardt HC, Feng Y, Sharp PA, Sonenberg N, White FM, Yaffe MB. 14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature, 2007, 446:329-32.
  47. Freire R, van Vugt MA, Mamely I, Medema RH. Claspin: timing the cell cycle arrest when the genome is damaged. Cell Cycle, 2006, 5:2831-4
  48. van Vugt MA,* Mamely I,* Smits VA, Semple JI, Lemons B, Perrakis A, Medema RH, Freire R. Polo-like kinase-1 controls proteasome-dependent degradation of Claspin during checkpoint recovery. Current Biology, 2006, 16:1950-5. (* equal contribution)
  49. Tanenbaum ME, Galjart N, van Vugt MA*, Medema RH*. CLIP-170 facilitates the formation of kinetochore-microtubule attachments. EMBO Journal, 2006, 25:45-57 (* equal contribution)
  50. van Vugt MA, Bras A, Medema RH. Restarting the cell cycle when the checkpoint comes to a halt. Cancer Research, 2006, 65:7037-40
  51. van Vugt MA, Medema RH. Getting in and out of mitosis with Polo-like kinase-1. Oncogene, 2005, 24:2844-59
  52. van Vugt MA, Medema RH. Polo-like kinase-1: activity measurement and RNAi-mediated knockdown. Methods in Molecular Biology, 2005, 296: 355-369
  53. van de Weerdt BC, van Vugt MALindon C, Kauw JJ, Rozendaal MJ, Klompmaker R, Wolthuis RM, Medema RH. Uncoupling anaphase-promoting complex/cyclosome activity from spindle assembly checkpoint control by deregulating polo-like kinase 1. Molecular and Cellular Biology, 2005, 25:2031-44.
  54. van Vugt MA, Bras A, Medema RH. Checkpoint adaptation and recovery: back with Polo after the break. Cell Cycle, 2004, 3:1383-6
  55. van Vugt MA,* Bras A,* Medema RH. Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Molecular Cell, 2004, 15:799-811. (* equal contribution)
  56. van Vugt MA, Van de Weerdt, BC, Vader G, Klompmaker R, Jansen H, Calafat G, Wolthuis RM, Medema RH. Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. Journal of Biological Chemistry, 2004, 279:36841-54
  57. van Vugt MA, Smit VA, Klompmaker R, Medema RH. Inhibition of Polo-like kinase-1 by DNA damage occurs in an ATM- or ATR-dependent fashion. Journal of Biological Chemistry, 2001, 276:41656-60